Metagenomi (NASDAQ:MGX) PT Lowered to $15.00

Metagenomi (NASDAQ:MGX) had its price objective lowered by investment analysts at Chardan Capital from $17.00 to $15.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 354.55% from the company’s previous close.

Several other research analysts have also recently commented on MGX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Metagenomi in a research report on Monday, July 15th. JPMorgan Chase & Co. cut shares of Metagenomi from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $16.00 to $6.00 in a research note on Thursday, May 2nd. Finally, BMO Capital Markets decreased their target price on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Metagenomi Stock Up 4.8 %

Metagenomi stock opened at $3.30 on Monday. Metagenomi has a 12 month low of $2.76 and a 12 month high of $12.74. The firm has a 50 day moving average price of $4.11.

Institutional Investors Weigh In On Metagenomi

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new stake in Metagenomi during the 1st quarter worth $1,894,000. XTX Topco Ltd acquired a new position in shares of Metagenomi in the 2nd quarter valued at $66,000. Rhumbline Advisers bought a new position in shares of Metagenomi in the 2nd quarter worth $26,000. Novo Holdings A S grew its stake in shares of Metagenomi by 3.5% during the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock worth $7,344,000 after purchasing an additional 60,825 shares during the period. Finally, Resolute Advisors LLC increased its holdings in Metagenomi by 165.0% in the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock valued at $108,000 after purchasing an additional 16,500 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.